#Uml editor comparison trial

Additionally, a standard representation would help create more homegeneous clinical trials, which would in turn facilitate the implementation of better meta analyses. This may, at least partly, be due to the lack of standard computational representation for these workflows, which would facilitate an operational comparison of how clinical trials are being conducted around the world. Despite this, little research has been conducted to analyze and/or compare the workflow of clinical trials, let alone those operating across international boundaries.

#Uml editor comparison trial

Such variation in clinical practice guidelines among emerging sites has ethical implications, as well as implications on the trial workflow and validity of results. For example, a 2001 FDA report notes that clinical trial вЂњsponsors have raised concerns regarding the capacity of the institutional review boards in some of the emerging sites to adequately review research according to Good Clinical Practice Guidelines, under the International Conference on Harmonization or FDA standardsвЂќ. Ultimately, the relative performance of clinical trials in emerging countries will depend on the internal workflow of these research sites and the establishment of good clinical trials practice guidelines.

ДЄlthough the globalization of clinical trials brings many potential benefits, a major challenge is faced regarding the standardization of clinical trials conducted in different parts of the world the workflows of clinical trials, as well as the standards of care in different countries may vary so much as to invalidate individual trial results. A study of industry sponsored phase 3 clinical trials in 2007 revealed that a majority of the sites were outside the United States. Between 19, the number of countries conducting drug research tracked by the Food and Drug Administration rose from 28 to 79, and by one recent estimate, 24 of the fastest 25 growing countries in clinical trials are in emerging, non-traditional areas. Clinical trials, though historically dominated by the United States and a small subset of countries in North America and Western Europe, are increasingly becoming a global activity with potential implications on health care delivery around the world.